CY1119188T1 - Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας - Google Patents

Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας

Info

Publication number
CY1119188T1
CY1119188T1 CY20171100843T CY171100843T CY1119188T1 CY 1119188 T1 CY1119188 T1 CY 1119188T1 CY 20171100843 T CY20171100843 T CY 20171100843T CY 171100843 T CY171100843 T CY 171100843T CY 1119188 T1 CY1119188 T1 CY 1119188T1
Authority
CY
Cyprus
Prior art keywords
extrinsic
cyclo
achievement
beta
liquids
Prior art date
Application number
CY20171100843T
Other languages
English (en)
Inventor
Roger Christopher Adami
Frederick David
Julia Ann Wood
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119188(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY1119188T1 publication Critical patent/CY1119188T1/el

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

Η παρούσα εφεύρεση κατευθύνεται σε φαρμακευτικές συνθέσεις που περιέχουν θεραπευτικώς αποτελεσματική ποσότητα δραστικού φαρμακευτικού συστατικού ("API"), φαρμακευτικώς αποδεκτή κυκλοδεξτρίνη και φαρμακευτικώς αποδεκτό συντηρητικό. Η εφεύρεση επίσης κατευθύνεται σε φαρμακευτικές συνθέσεις των ενώσεων του Τύπου (I) όπου R2 επιλέγεται από την ομάδα που αποτελείται από μεθύλ, αιθύλ, ισοπροπύλ, δευτ.-βουτύλ και τ-βουτύλ και φαρμακευτικώς αποδεκτή κυκλοδεξτρίνη και συντηρητικό. Τύπος (I): Ειδικότερα, η εφεύρεση κατευθύνεται σε φαρμακευτικές συνθέσεις της ένωσης του τύπου 1a και φαρμακευτικώς αποδεκτή κυκλοδεξτρίνη και συντηρητικό.
CY20171100843T 2004-01-30 2017-08-04 Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας CY1119188T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54089704P 2004-01-30 2004-01-30
PCT/IB2005/000100 WO2005082416A2 (en) 2004-01-30 2005-01-17 Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms

Publications (1)

Publication Number Publication Date
CY1119188T1 true CY1119188T1 (el) 2018-02-14

Family

ID=34910697

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100843T CY1119188T1 (el) 2004-01-30 2017-08-04 Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας

Country Status (25)

Country Link
US (1) US8183230B2 (el)
EP (1) EP1713504B1 (el)
JP (1) JP5021318B2 (el)
KR (1) KR100834232B1 (el)
CN (1) CN101090735A (el)
AR (2) AR047469A1 (el)
AU (1) AU2005216709B2 (el)
BR (1) BRPI0506496B8 (el)
CA (1) CA2554346C (el)
CO (1) CO5700794A2 (el)
CY (1) CY1119188T1 (el)
DK (1) DK1713504T3 (el)
ES (1) ES2638113T3 (el)
HU (1) HUE034099T2 (el)
IL (1) IL176676A0 (el)
LT (1) LT1713504T (el)
NO (1) NO20063858L (el)
NZ (1) NZ548236A (el)
PL (1) PL1713504T3 (el)
PT (1) PT1713504T (el)
RU (1) RU2332997C2 (el)
SI (1) SI1713504T1 (el)
TW (1) TW200524632A (el)
WO (1) WO2005082416A2 (el)
ZA (1) ZA200605148B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506273PA (en) * 2011-11-29 2015-09-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
KR102455648B1 (ko) * 2013-07-19 2022-10-19 베링거잉겔하임베트메디카게엠베하 보존된 에테르화된 사이클로덱스트린 유도체 함유 액체 수성 약제학적 조성물
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
AU2018251604B2 (en) 2017-04-10 2022-04-14 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
CA3129648A1 (en) * 2019-02-15 2020-08-20 Saol International Limited Injectable phenol formulations and methods of their use
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置
KR100214905B1 (ko) 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
EP0668863B1 (en) 1992-11-12 1997-01-08 Pfizer Inc. Quinuclidine derivative as substance p antagonist
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP1109581A1 (en) 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6255320B1 (en) 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
AU5975700A (en) 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
CZ200434A3 (cs) 2001-07-20 2005-02-16 Pfizer Products Inc. Léčivo pro léčení abnormálního úzkosného chování u domácích zvířat a způsob screeningu zkoušené sloučeniny za účelem stanovení anxiolytické účinnosti u psů
US20040019012A1 (en) 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
US20070155782A1 (en) 2004-01-30 2007-07-05 Hickman Mary A Nk-1 receptor antagonists anesthesia recovery
MXPA06008648A (es) 2004-01-30 2006-09-04 Pfizer Prod Inc Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion.
PT1713801E (pt) 2004-02-02 2008-02-11 Pfizer Prod Inc Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina

Also Published As

Publication number Publication date
WO2005082416A3 (en) 2006-07-27
NZ548236A (en) 2010-02-26
NO20063858L (no) 2006-10-19
RU2006127422A (ru) 2008-03-10
PT1713504T (pt) 2017-08-29
ZA200605148B (en) 2007-10-31
KR100834232B1 (ko) 2008-05-30
IL176676A0 (en) 2006-10-31
JP5021318B2 (ja) 2012-09-05
EP1713504A2 (en) 2006-10-25
SI1713504T1 (sl) 2017-10-30
BRPI0506496A (pt) 2007-02-13
CO5700794A2 (es) 2006-11-30
EP1713504B1 (en) 2017-06-07
DK1713504T3 (en) 2017-08-07
KR20060128973A (ko) 2006-12-14
RU2332997C2 (ru) 2008-09-10
LT1713504T (lt) 2017-09-11
CN101090735A (zh) 2007-12-19
CA2554346C (en) 2009-11-17
AR047469A1 (es) 2006-01-18
HUE034099T2 (en) 2018-01-29
PL1713504T3 (pl) 2017-12-29
BRPI0506496B1 (pt) 2018-10-09
BRPI0506496B8 (pt) 2022-09-20
AU2005216709A1 (en) 2005-09-09
WO2005082416A2 (en) 2005-09-09
JP2007519703A (ja) 2007-07-19
BRPI0506496A8 (pt) 2017-11-14
US20070155697A1 (en) 2007-07-05
AU2005216709B2 (en) 2008-02-07
TW200524632A (en) 2005-08-01
ES2638113T3 (es) 2017-10-18
AR109357A2 (es) 2018-11-21
US8183230B2 (en) 2012-05-22
CA2554346A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CY1119188T1 (el) Αντιμικροβιακα συντηρητικα για την επιτευξη φαρμακοτεχνικης μορφης πολλαπλης δοσης χρησιμοποιωντας βητα-κυκλοεξτρινες για υγρες μορφες δοσολογιας
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
FR2805817B1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
NO20043367L (no) Oralt farmasoytisk preparat
ATE297203T1 (de) Antithrombotische mitteln
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
WO2005117895A8 (en) Compositions comprising meloxicam
WO2003004098A8 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
DE602005025493D1 (de) Entzündungshemmende wirkstoffe
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
DK1414467T3 (da) Topisk behandling af mastalgi
SE0002476D0 (sv) New compounds
ATE308540T1 (de) Antithrombosemittel
EP2199300A3 (en) Peptidic compounds
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
DE60109465D1 (de) Extrakte des pilzes guignardia sp., deren verwendung in pharmazeutischen verbindungen; neu isolierte verbindung aus guignardia sp. pilzextrakten und deren verwendung in pharmazeutischen präparaten
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
MA30179B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique.
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
BR0213463A (pt) Composições farmacêuticas contendo macrólidos